Stephen J Freedland, MD

Aggarwal R et al. PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19). ESMO 2022;Abstract LBA63.

Attard G et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: A meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 2022;399(10323):447-60. Abstract

Shore N et al. EMBARK: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer. AUA 2023;Abstract LBA02-09.

Fred Saad, MD, FRCS

Fizazi K et al. A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1. ESMO 2021;Abstract LBA5_PR.

Saad F et al. Prostate-specific antigen analyses in PROpel: Abiraterone and olaparib versus abiraterone and placebo as first-line therapy for metastatic castration-resistant prostate cancer. AUA 2022;Abstract MP11-16.

Neal D Shore, MD, FACS

Agarwal N et al. CYCLONE 1: Abemaciclib in men with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC). AACR 2023;Abstract CT159.

Agarwal N et al. TALAPRO-2: Phase 3 study of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer. Genitourinary Cancers Symposium 2023;Abstract LBA17.

Chi K et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. Genitourinary Cancers Symposium 2022;Abstract 12.

Clarke NW et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evidence 2022;1(9). Abstract

Saad F et al. PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium 2022;Abstract 11.

Matthew R Smith MD, PhD

Agarwal N et al. TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium 2023;Abstract LBA17.

Agarwal N et al. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncol 2022;18(4):425-36. Abstract

Clarke NW et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evidence 2022;1(9). Abstract

Fizazi K et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med 2023;388(8):719-32. Abstract

Saad F et al. PROpel: Phase III trial of olaparib (ola) and abiraterone (abi)  versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium 2022;Abstract 11.

Smith MR et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): A multicentre, open-label, phase 2 trial. Lancet Oncol 2022;23(3):362-73. Abstract

Himisha Beltran, MD

Bakht MK et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer 2023;[Online ahead of print]. Abstract

Buteau JP et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): A biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol 2022;23(11):1389-97. Abstract

Rahbar K et al. Safety and survival outcomes of 177Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate cancer with prior 223Ra treatment: The RALU study. J Nucl Med 2023;64(4):574-8. Abstract